| Literature DB >> 25877692 |
Junya Ishikawa1, Naoki Hayashi1, Masaru Yamaguchi1, Satoru Monzen1, Ikuo Kashiwakura2.
Abstract
To clarify the mechanisms underlying radiation-induced hematopoietic stem cell death, we investigated the effects of excessive ionizing radiation on the clonogenic potential of CD34(+) cells obtained from human umbilical cord blood under cytokine-free conditions. The CD34(+) cells were X-ray-irradiated (up to 2 Gy) and were cultured for 0-48 h under cytokine-free conditions. At various time-points, the CD34(+) cells were investigated for survival, clonogenic potential and the generation of mitochondrial superoxide. At 12 h after X-ray irradiation, the number of viable cells had decreased to ∼70-80% compared with the 0-h non-irradiated control, whereas the clonogenic potential in the X-ray-irradiated cells had decreased to ∼50%-60% compared with the 0-h non-irradiated control. Furthermore, significant generation of mitochondrial superoxide was observed at 6 h, and reached a maximum value between 12 and 24 h after X-ray irradiation. However, no significant differences were observed between non-irradiated and X-ray-irradiated cells in terms of the generation of reactive oxygen species or in the intracellular mitochondrial contents. In addition, a cDNA microarray analysis showed that the majority of the altered genes in the CD34(+) cells at 6 h after X-ray irradiation were apoptosis-related genes. These results suggest the possibility that the elimination of the clonogenic potentials of CD34(+) cells involves the generation of mitochondrial superoxide induced by ionizing radiation.Entities:
Keywords: CD34+ cells; clonogenic potential; radiation; superoxide
Mesh:
Substances:
Year: 2015 PMID: 25877692 PMCID: PMC4497397 DOI: 10.1093/jrr/rrv024
Source DB: PubMed Journal: J Radiat Res ISSN: 0449-3060 Impact factor: 2.724
Fig. 1.The survival of the CD34+ cells cultured in cytokine-free medium with or without irradiation. Non-irradiated or X-ray–irradiated CD34+ cells were seeded and cultured under serum- and cytokine-free conditions, as described in the Materials and Methods. After the indicated period of incubation, all cells cultured under each condition were harvested, and viable cells were counted by the trypan blue exclusion test. The values are the means ± standard deviation (S.D.) of more than three separate experiments performed in duplicate wells. *P < 0.05, by the Tukey–Kramer test.
Fig. 2.The clonogenic potential of the CD34+ cells cultured in cytokine-free medium with or without irradiation. The CFCs, including CFU-GM, BFU-E and CFU-Mix populations, were assayed by the methylcellulose method, as described in the Materials and Methods. Colonies containing >50 cells were counted using an inverted microscope. The values are the means ± S.D. of more than three separate experiments performed in duplicate wells. *P < 0.05, by the Tukey–Kramer test.
Fig. 3.The alteration of the expression of cell surface antigens on the CD34+ cells cultured in cytokine-free medium with or without irradiation. The expression of specific cell surface antigens was analyzed by direct immunofluorescence flow cytometry, as described in the Materials and Methods. The values are the means ± S.D. of more than three separate experiments in duplicate wells. *P < 0.05, by the Tukey–Kramer test.
The cell cycle distribution of human CD34+ cells cultured in serum/cytokine-free medium with or without irradiation
| Time | Phase | 0 Gy | 0.5 Gy | 2 Gy |
|---|---|---|---|---|
| 0 h | Sub G1 | 20.76 ± 2.22% | ||
| G0/G1 | 73.22 ± 3.64% | |||
| S/G2/M | 5.67 ± 3.76% | |||
| 12 h | Sub G1 | 34.67 ± 12.49% | 45.51 ± 0.73%* | 41.00 ± 1.00%* |
| G0/G1 | 54.13 ± 7.68% | 46.90 ± 2.06%* | 49.47 ± 1.89% | |
| S/G2/M | 11.20 ± 4.98% | 7.49 ± 2.10% | 9.53 ± 1.80% | |
| 24 h | Sub G1 | 25.17 ± 8.18% | 25.90 ± 9.16% | 25.38 ± 4.70% |
| G0/G1 | 63.94 ± 16.23% | 67.65 ± 13.25% | 66.66 ± 8.50% | |
| S/G2/M | 10.91 ± 8.43% | 6.45 ± 4.18% | 7.97 ± 4.48% | |
| 48 h | Sub G1 | 17.81 ± 11.06% | 10.14 ± 5.56% | 10.96 ± 3.13% |
| G0/G1 | 78.88 ± 11.05% | 86.93 ± 7.52% | 86.11 ± 3.93% | |
| S/G2/M | 3.29 ± 2.27% | 2.93 ± 1.96% | 2.93 ± 0.81% |
The cell cycle distribution was analyzed by flow cytometry. In the cells exposed to X-ray irradiation, the percentage of cells in the Sub G1 phase at 12 h was significantly increased compared with the control. The values are the means ± S.D. of more than three separate experiments. *P < 0.05, by the Tukey–Kramer test.
Fig. 4.Intracellular mitochondrial content, intracellular reactive oxygen species content and mitochondrial superoxide content in CD34+ cells cultured in cytokine-free medium with or without irradiation. These parameters were analyzed by flow cytometry, as described in the Materials and Methods. The values are the means ± S.D. of at least three separate experiments. *P < 0.05, by the Tukey–Kramer test.
Fig. 5.The results of the cDNA microarray analysis of the CD34+ cells cultured in cytokine-free medium with or without irradiation. According to the Ingenuity Pathway Analysis knowledge, the number of significantly altered genes that were known to be associated with apoptosis were classified according to their localization. A comparison of each gene was conducted between 0 h non-irradiated cells and the cells subjected to each treatment for the various time-points.
The upregulated apoptosis-related genes in the nuclei of X-ray–irradiated CD34+ cells cultured under cytokine-free conditions
| Symbol | Entrez gene name | Fold change |
|---|---|---|
| Cyclin-dependent kinase inhibitor 1 | 5.04 | |
| Cyclin 1 | 4.27 | |
| Ribosomal protein S8 kinase, 90 kDa, polypeptide 5 | 4.26 | |
| MDM2 oncogene, E3 ubiquitin protein ligase | 4.04 | |
| Polo-like kinase 2 | 3.72 | |
| Polo-like kinase 3 | 3.58 | |
| Nuclear receptor subfamily 4, group A, member 1 | 3.52 | |
| Peroxisome proliferator-activated receptor delta | 3.44 | |
| Protein inhibitor of activated STAT, 2 | 3.32 | |
| GLI family zinc finger 2 | 3.25 | |
| GLI family zinc finger 3 | 3.22 | |
| Homeodomain interacting protein kinase 3 | 3.18 | |
| Yes-associated protein 1 | 3.08 | |
| Growth arrest and DNA-damage-inducible, alpha | 3.02 | |
| Aryl-hydrocarbon receptor nuclear translocator 2 | 2.97 | |
| Damage-specific DNA binding protein 2, 48 kDa | 2.93 | |
| Homeodomain interacting protein kinase 2 | 2.78 | |
| Polymerase (DNA directed), eta | 2.76 | |
| FOS-like antigen 1 | 2.70 | |
| Zinc finger, matrin-type 3 | 2.70 | |
| Vitamin D (1,25-dihydroxyvitamin D3) receptor | 2.57 | |
| GATA binding protein 4 | 2.57 | |
| Large tumor suppressor, homolog 2 | 2.55 | |
| Early growth response 4 | 2.51 | |
| Endothelial PAS domain protein 1 | 2.50 | |
| Polymerase (RNA) II (DNA directed) polypeptide A, 220kDa | 2.49 | |
| Ribosomal protein S27-like | 2.46 | |
| Serine/threonine kinase 17a | 2.46 | |
| Proliferating cell nuclear antigen | 2.45 | |
| Autoimmune regulator | 2.44 | |
| Ubiquitin protein ligase E3 component n-recognin 4 | 2.43 | |
| B-cell CLL/lymphoma 3 | 2.43 | |
| Zic family member 1 | 2.39 | |
| Large tumor suppressor, homolog 1 | 2.38 | |
| Forkhead box C1 | 2.38 | |
| Activating transcription factor 3 | 2.36 | |
| GATA zinc finger domain containing 2A | 2.35 | |
| E2F transcription factor 1 | 2.32 | |
| Early growth response 1 | 2.31 | |
| Xeroderma pigmentosum, complementation group C | 2.29 | |
| V-ets erythroblastosis virus E26 oncogene homolog 1 | 2.29 | |
| Kv channel interacting protein 3, calsenilin | 2.27 | |
| Nuclear receptor coactivator 3 | 2.25 | |
| Serine/arginine-rich splicing factor 1 | 2.24 | |
| Distal-less homeobox 2 | 2.21 | |
| IKAROS family zinc finger 3 | 2.21 | |
| Interferon regulatory factor 4 | 2.14 | |
| Promyelocytic leukemia | 2.14 | |
| SPO11 meiotic protein covalently bound to DSB homolog | 2.12 | |
| HECT, UBA and WWE domain contaiing 1, E3 ubiquitin protein ligase | 2.08 | |
| Progesterone receptor | 2.06 | |
| Retinoblastoma-like 1 | 2.05 | |
| B-cell CLL/lymphoma 6 | 2.04 | |
| Serum response factor (c-fos serum response element-binding transcription factor)factor) | 2.03 | |
| Suppressor of zeste 12 homolog | 2.03 | |
| Runt-related transcription factor 1 | 2.03 | |
| Lanin A/C | 2.02 | |
| Nuclear receptor coactivator 6 | 2.00 |
The cDNA microarray analysis was performed using the Gene Chip system and GeneSpring GX software program as described in the Materials and Methods.
The downregulated apoptosis-related genes in the nuclei of X-ray–irradiated CD34+ cells cultured under cytokine-free conditions
| Symbol | Entrez gene name | Fold change |
|---|---|---|
| Activating transcription factor 2 | 8.29 | |
| Activating transcription factor 3 | 5.10 | |
| Zinc finger protein 423 | 4.80 | |
| Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, | 4.34 | |
| Antigen identified by monoclonal antibody Ki-67 | 4.23 | |
| PRKC, apoptosis, WT1, regulator | 4.20 | |
| Cell division cycle 25C | 3.52 | |
| Synaptonemal complex protein 2 | 3.26 | |
| Hepatic leukemia factor | 3.20 | |
| Lymphoid enhancer-binding factor 1 | 3.17 | |
| Cyclin-dependent kinase 6 | 3.12 | |
| Transition protein 2 (during histone to protamine replacement) | 2.95 | |
| SMAD family member 6 | 2.93 | |
| Calcium/calmodulin-dependent protein kinase IV | 2.87 | |
| Zinc finger protein 622 | 2.87 | |
| Glycogen synthase kinase 3 beta | 2.80 | |
| SWI/SNF related, matrix associated, actin dependent regulator of chromatin | 2.71 | |
| Friend leukemia virus integration 1 | 2.64 | |
| TSC22 domain family, member 1 | 2.62 | |
| SRY (sex determining region Y)-box 5 | 2.61 | |
| Rho GTPase activating protein 35 | 2.50 | |
| SATB homeobox 1 | 2.49 | |
| Protein phosphatase 5, catalytic subunit | 2.45 | |
| SMAD family member 3 | 2.44 | |
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, delta | 2.43 | |
| SRY (sex determining region Y)-box 6 | 2.40 | |
| Runt-related transcription factor 1; translocated to, 1 (cyclin D-related) | 2.39 | |
| Thymidylate synthetase | 2.31 | |
| SRY (sex determining region Y)-box 17 | 2.29 | |
| Ras association (RalGDS/AF-6) domain family member 1 | 2.28 | |
| Recombinant activating gene 1 | 2.26 | |
| Hairy/enhancer-of-split related with YRPW motif 1 | 2.25 | |
| Zinc finger E-box binding homeobox 2 | 2.23 | |
| Regucalcin (senescence marker protein-30) | 2.17 | |
| Methionine sulfoxide reductase B2 | 2.16 | |
| Early B-cell factor 1 | 2.16 | |
| NK2 homeobox 5 | 2.14 | |
| V-rel reticuloendothellosis viral oncogene homolog A (avian) | 2.14 | |
| Estrogen receptor 1 | 2.13 | |
| Nuclear receptor coactivator 2 | 2.12 | |
| Testis expressed 11 | 2.10 | |
| Iroquois homeobox 1 | 2.09 | |
| Nuclear receptor subfamily 1, group I, member 3 | 2.08 | |
| Cysteine-serine-rich nuclear protein 3 | 2.05 | |
| Neuro-oncological ventral antigen 1 | 2.05 | |
| Inhibitor of growth family, member 5 | 2.04 | |
| T-cell acute lymphocytic leukemia 1 | 2.03 | |
| High mobility group AT-hook 2 | 2.01 |
The cDNA microarray analysis was performed using the Gene Chip system and the GeneSpring GX software program as described in the Materials and Methods.